Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2, 2010, Pages 383-389

  Massanari, Marc ^a   Nelson, Harold ^b   Casale, Thomas ^c   Busse, William ^d   Kianifard, Farid ^a   Geba, Gregory P ^a   Zeldin, Robert K ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DEPARTMENT OF MEDICINE   (United States)

^c CREIGHTON UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

allergic asthma; cat; cluster immunotherapy; dog; house dust mites; immunotherapy; Omalizumab; systemic allergic reactions

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; HOUSE DUST ALLERGEN; OMALIZUMAB; PLACEBO; STEROID;

ADULT; ALLERGIC ASTHMA; ALLERGIC REACTION; ANAPHYLAXIS; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CAT; CELLULITIS; CHEST TIGHTNESS; CLINICAL TRIAL; COLLAPSE; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYANOSIS; DIZZINESS; DOG; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; HEART ARRHYTHMIA; HOARSENESS; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INDUCED ABORTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MULTICENTER STUDY; NAUSEA; NOSE DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; SEXUAL ABUSE; SIDE EFFECT; SINUSITIS; SPINAL CORD TUMOR; STOMACH PAIN; STRIDOR; TREATMENT DURATION; URTICARIA; VOMITING; WHEEZING;

ADOLESCENT; ADULT; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CATS; DESENSITIZATION, IMMUNOLOGIC; DOGS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; PYROGLYPHIDAE; YOUNG ADULT;

EID: 75849151415     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.022     Document Type: Article

References (22)

1. Adkinson Jr. N.F. Immunotherapy for allergic rhinitis. N Engl J Med 341 (1999) 522-524
2. Lockey R.F. ARIA: global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 108 (2001) 497-499
3. Abramson M.J., Puy R.M., and Weiner J.M. Allergen immunotherapy for asthma (review). Cochrane Database Syst Rev 4 (2003) CD001186
4. Bernstein D.I., Wanner M., Borish L., Liss G.M., Immunotherapy Committee of the American Academy of Allergy, and Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113 (2004) 1129-1136
5. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
6. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112 (2003) 1147-1154
7. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
8. Solèr M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261
9. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., et al., The Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117 (2006) 134-140
10. Kuehr J., Brauburger J., Zielen S., Schauer U., Kamin W., Von Berg A., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109 (2002) 274-280
11. Ewbank P.A., Murray J., Sanders K., Curran-Everett D., Dreskin S., and Nelson H.S. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 111 (2003) 155-161
12. Walker S.M., Pajno G.B., Lima M.T., Wilson D.R., and Durham S.R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 107 (2001) 87-93
13. Cox L. Advantages and disadvantages of accelerated immunotherapy schedules. J Allergy Clin Immunol 122 (2008) 432-434
14. Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention. Revised 2006. Available at: http://www.ginasthma.org/. Accessed September 22, 2009.
15. Müller H.L. Diagnosis and treatment of insect sensitivity. J Asthma Res 3 (1966) 331-333
16. Collett D. Modelling survival data in medical research. 2nd ed. (2003), Chapman & Hall/CRC, New York
17. Lachin J.M. Biostatistical methods: the assessment of relative risks (2000), Wiley, New York
18. Stokes M.E., Davis C.S., and Koch G.G. Categorical data analysis using the SAS system. 2nd ed. (2000), SAS Institute, Inc, Cary (NC)
19. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1 (1982) 121-129
20. Nielsen L., Johnsen C.R., Mosbech H., Paulsen L.K., and Malloy H.-J. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 97 (1996) 1207-1213
21. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. In press 2009.
22. Rolinck-Werninghaus C., Hamelmann E., Keil T., Kulig M., Koetz K., Gerstner B., et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59 (2004) 973-979